9 Meters Biopharma, Inc. (NMTR) stock falls in Pre-Market: Why is it so?
9 Meters Biopharma, Inc. (NASDAQ: NMTR), a clinical-stage biopharmaceutical company specializing in treatments for rare diseases with unmet medical attention. , announced that the Company’s Chief Executive Officer, John Temperato will report a corporate update at Oppenheimer’s Rare & Orphan Disease Summit. NMTR stock price declined adjacent to the news. At last check-in premarket trading, […]
That’s how 9 Meters Biopharma (NMTR) stock staying above the limits
A biotechnology firm, 9 Meters Biopharma (NMTR), focuses on patients with rare diseases and unmet needs. The company’s portfolio contains drug candidates with short bowel syndrome (SBS) and celiac disease. Get the hottest stocks to trade every day before the market opens 100% free. Click here now. Recent Scores The Company with a Market Cap […]
Here is the reason why 9 Meters Biopharma, Inc. (NMTR) stock rushed in the late trading session
9 Meters Biopharma, Inc. (NASDAQ:NMTR) shares surged 18.56 to $0.89 in the post-market session after the Company has announced that it has closed its previously announced underwritten public offering of 53,076,924 shares of its common stock, inclusive of the full over allotment option exercised by the underwriters for the price of $0.65 per share. About […]
